What are the differences between methicillin‑susceptible Staphylococcus aureus (MSSA) and methicillin‑resistant Staphylococcus aureus (MRSA), particularly regarding antibiotic susceptibility and recommended treatment?

MSSA vs MRSA: Key Differences and Treatment Implications

The fundamental difference between MSSA and MRSA is antibiotic susceptibility: MSSA responds to β-lactam antibiotics (nafcillin, oxacillin, cefazolin), while MRSA requires alternative agents (vancomycin, daptomycin, linezolid) due to resistance mediated by the mecA gene encoding altered penicillin-binding protein 2a (PBP2a). 1

Microbiological Distinction

Resistance Mechanism:

• MRSA carries the mecA gene producing PBP2a, conferring resistance to all β-lactam antibiotics including methicillin, nafcillin, oxacillin, and most cephalosporins 1
• MSSA lacks this resistance mechanism and remains susceptible to β-lactams 1

Laboratory Detection:

• Use cefoxitin 30 mcg disk as the most accurate surrogate test for methicillin resistance
• MRSA: cefoxitin zone ≤21 mm (or cefoxitin MIC ≥8 mcg/mL)
• MSSA: cefoxitin zone ≥22 mm (or cefoxitin MIC ≤4 mcg/mL)
• Direct mecA or PBP2a testing provides definitive confirmation 1

Treatment Differences

For MSSA Infections:

Preferred agents (once susceptibility confirmed):

• Cefazolin or antistaphylococcal penicillins (nafcillin, oxacillin) 2, 3
• These β-lactams are superior to vancomycin for MSSA and should replace empiric MRSA coverage once susceptibilities return 3

For MRSA Infections:

Empiric therapy options (pending cultures):

Outpatient skin/soft tissue infections:

• Clindamycin (oral)
• TMP-SMX (oral)
• Doxycycline or minocycline (oral)
• Linezolid (oral) 4

Hospitalized/complicated infections:

• Vancomycin (IV) - first-line
• Daptomycin 4 mg/kg IV daily
• Linezolid 600 mg IV/PO twice daily
• Telavancin 10 mg/kg IV daily 4

Critical caveat: For serious MRSA infections including bacteremia, vancomycin or daptomycin are standard, with recent data showing noninferiority between these agents (treatment success ~44-70% depending on infection severity) 3

Clinical Outcome Differences

MRSA infections demonstrate:

• Higher rates of complications requiring ICU admission, mechanical ventilation, and vasopressor support, particularly in bacteremia, osteoarticular infections, and pneumonia 5
• More surgical interventions required for osteoarticular MRSA (89% vs 61% needing >1 surgery for MSSA) 5
• Trend toward higher 6-month all-cause mortality (26% vs 7%, though not statistically significant in some studies) 6
• Significantly higher likelihood of receiving inappropriate empirical antibiotics (93% vs 0%) since most empiric regimens cover MSSA but not MRSA 6

MRSA patient characteristics:

• Tend to be older (mean age 76 vs 44 years for MSSA)
• More comorbidities (mean 2.7 vs 1.35)
• More commonly nosocomial or associated with IV lines/soft tissue infections
• MSSA more associated with IV drug use 6

Antibiotic Susceptibility Patterns

MRSA shows significantly higher resistance rates to:

• Clindamycin (45.7% resistant)
• Ciprofloxacin (64.7% resistant)
• Cotrimoxazole (87.3% resistant)
• Erythromycin (54.3% resistant)
• Tetracycline (58.4% resistant)
• Inducible clindamycin resistance detected in 21.4% of MRSA strains 7

Both MSSA and MRSA:

• Universally susceptible to vancomycin (100% susceptibility maintained) 7
• Nearly universally resistant to penicillin G 7

Important trend: Recent data shows MRSA becoming MORE sensitive to ciprofloxacin over time, while MSSA paradoxically developing MORE resistance to ciprofloxacin, clindamycin, gentamicin, and TMP-SMX 8

Practical Treatment Algorithm

1. Obtain cultures from all purulent sites and blood before starting antibiotics 4

2. Start empiric therapy:

   • If MRSA risk factors present (nosocomial, IV lines, known colonization, severe infection): Use vancomycin or daptomycin
   • If low MRSA risk: May use cefazolin, but switch to MRSA coverage if no clinical response in 48-72 hours 4

3. De-escalate based on susceptibilities:

   • If MSSA: Switch to cefazolin or nafcillin/oxacillin immediately 2, 3
   • If MRSA: Continue vancomycin, daptomycin, or linezolid 4

4. Duration:

   • Skin/soft tissue: 5-10 days (individualized to clinical response)
   • Complicated infections: 7-14 days minimum
   • Bacteremia: Minimum 2 weeks if uncomplicated, longer if metastatic foci present 4

5. Source control is mandatory: Remove infected devices, drain abscesses, debride necrotic tissue 3

Key Pitfalls to Avoid

• Never continue vancomycin for MSSA once susceptibilities confirm methicillin-susceptibility—β-lactams are superior 3
• Do not use rifampin monotherapy or as routine adjunctive therapy for skin/soft tissue infections 4
• Test for inducible clindamycin resistance (D-test) before using clindamycin for MRSA, as 21% harbor this mechanism 7
• Obtain echocardiography for all S. aureus bacteremia cases; use TEE for high-risk patients (persistent bacteremia >48 hours, implanted devices, metastatic foci) 3